Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Counterfeit Harvoni Likely Entered Distribution before Reaching Pharmacies: MHLW Official
January 23, 2017
- MHLW to Take Prompt Action on Counterfeit Issue: Bureau Chief
January 20, 2017
- Details of Approvals to Be Provided to Prefectures Prior to Unannounced Inspections: MHLW Official
January 20, 2017
- Counterfeit Harvoni Discovered in Nara Pharmacy, MHLW Investigating Route of Entry into Distribution
January 18, 2017
- MHLW to Ponder Additional Gap-Year Price Survey Method That Won’t Cripple Single-Product, Single-Price Efforts: Kanda
January 17, 2017
- MHLW Task Force on “Data Health” to Compile Report by Summer
January 16, 2017
- PMDA Stops Increasing Review Staff, Current Review-Time Targets to Remain Unchanged: Chief Executive
January 16, 2017
- Industry Speculating Tax Hike Will Delay Annual Revision Rollout to 2021
January 13, 2017
- MHLW Panel on AI Use in Healthcare Boots Up
January 13, 2017
- Projection-Based Price Cuts, Instead of Ex-Post Reviews, Mooted for New Quarterly Scheme
January 12, 2017
- MHLW Wants Specific Plan by May for Four-Times Yearly Price Review of Indication-Added Drugs
January 12, 2017
- Chuikyo Industry, Doctor Reps in Discord over Scope of Price Review for Indication Expansions
January 12, 2017
- Revlimid Ordered to Add Label Warning for Hep B Virus Reactivation
January 11, 2017
- Chuikyo to Kick Off Debates to Elaborate Pricing Revamp; 2 Industry Hearing Sessions Planned
January 11, 2017
- “Drug Value Assessments Will Be Critical”; High-Priced Innovative Drugs to Be a Topic at OECD Meeting: Health Minister
January 10, 2017
- MHLW to Regularly Compile Optimal Drug Use Guidelines from FY2017: Pharma Bureau Chief
January 6, 2017
- From Regulatory Agency to Industry-Fostering Agency: Health Minister
January 5, 2017
- MHLW to Draw Up Genomic Medicine Project by Summer: Minister
January 5, 2017
- Policymakers Rolling Up Their Sleeves to Embody Drug Pricing Overhaul
January 1, 2017
- AMED Plans to Introduce Medical-Economic Viewpoints for Its R&D Support
December 28, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…